Adaptive Biotechnologies (ADPT) Stock Looks Fairly Valued At Today’s Price

Adaptive Biotechnologies has delivered a very strong 3 year share price gain, yet current valuation checks suggest the stock is not a clear bargain, with its intrinsic value estimate only slightly below the market price while market multiples lean rich. For investors, that mix makes it important to separate momentum from what the current price implies about future cash flows.

• Over the past 3 years the stock is up about 290%, which means existing shareholders have already seen a large part of the potential upside reflected in the price.
• The long term opportunity in Adaptive Biotechnologies may depend on how effectively it converts its immunosequencing platform into durable, cash generative products, while execution risk around timelines and profitability can weigh on what investors are willing to pay today.
• On Simply Wall St's broader checks, Adaptive Biotechnologies scores 1 out of 6 for value, which means the shares currently lean expensive rather than offering an obvious value cushion.

The issue now is whether Adaptive Biotechnologies' current price fairly reflects its intrinsic value or bakes in expectations that may be hard to meet.

Compare how Adaptive Biotechnologies stacks up against other stocks that screen as richly priced by checking 52 high quality undervalued stocks for alternatives with stronger value support.

Where Does Adaptive Biotechnologies Sit on Cash Flow?

The Discounted Cash Flow (DCF) model here uses a 2 stage Free Cash Flow to Equity approach to estimate what Adaptive Biotechnologies might be worth based on its future cash generation.

Adaptive Biotechnologies currently reports latest twelve month free cash flow of about $26.7 million in outflows, so the model assumes a recovery path where cash flows turn positive and grow over time rather than staying at current levels. On those projections, the DCF model points to an intrinsic value of about $23.63 per share. That sits only slightly below the recent share price, which implies the stock screens as roughly fairly valued on this method, with a small 4.0% premium to the modelled value.

On this DCF view, Adaptive Biotechnologies appears roughly fairly valued, with only a modest gap between the market price and its estimated intrinsic worth.

Adaptive Biotechnologies is fairly valued according to our Discounted Cash Flow (DCF), but this can change at a moment's notice. Track the value in your watchlist or portfolio and be alerted on when to act.

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Adaptive Biotechnologies.

Has Adaptive Biotechnologies Run Too Far on Sales?

P/S is a useful cross check for Adaptive Biotechnologies because revenue is a key reference point while the business is still working toward consistent free cash flow.

The stock trades on a P/S ratio of about 12.7x, compared with a Life Sciences industry average near 4.3x and a peer group average around 16.9x. On Simply Wall St’s fair multiple framework, a P/S of roughly 5.0x would be more in line with Adaptive Biotechnologies' size, risks and current fundamentals.

The gap between the current 12.7x and the fair 5.0x suggests the market is paying a sizeable premium for Adaptive Biotechnologies relative to what this model implies revenue is worth today.

On this P/S measure, Adaptive Biotechnologies stock appears overvalued compared with both its industry and the tailored fair multiple estimate.

See what the numbers say about this price — find out in our valuation breakdown.

The Adaptive Biotechnologies Narrative: What Would Justify Today's Price?

Simply Wall St Narratives take the valuation puzzle around Adaptive Biotechnologies and turn it into a set of clear what if paths that spell out which growth, margin and earnings outcomes would need to play out for the stock to be worth much more or much less than today’s price. They sit on the company’s Community page so you can see how each scenario links its number to a view on future growth, profitability and risk that can be revisited as new information arrives.

One of the top community narratives on Adaptive Biotechnologies: roughly fairly valued

"Accelerating integration of clonoSEQ into electronic medical records (EMRs) across both academic and community settings, as well as the major rollout with Flatiron's OncoEMR and expansion through partnerships like NeoGenomics, streamlines ordering and supports recurring test usage, which is expected to drive strong multi-year clinical volume growth and recurring revenue..."

Read one of the top narratives on Adaptive Biotechnologies

Do you think there's more to the story for Adaptive Biotechnologies? Head over to our Community to see what others are saying!

The Bottom Line

For Adaptive Biotechnologies, the Discounted Cash Flow (DCF) work suggests the current price is close to intrinsic value, so the easy valuation upside already looks limited. The market multiple view points to an overvalued stock on revenue, which lines up with the broader, weaker value checks. That split reflects investors paying up today for future growth and margin gains that are not yet fully proven in cash flow. The key question from here is whether Adaptive Biotechnologies can convert its platform into sustained, profitable revenue fast enough to justify both the current multiple and any further optimism.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com